|
Medtronic Biologic Therapeutics and Diagnostics
Hemostasis Management
Improved hemostasis management results in fewer complications associated with excessive blood loss,1 reduces hemostasis activation,2 and preserves the coagulation system.3 The associated benefits are reduced blood product utilization, fewer transfusions3 and decreased associated costs.4
Medtronic is proud to offer two systems that provide patients with proven hemostasis results:
The HMS Plus™ Hemostasis Management System is a reliable, versatile and effective platform for accurate hemostasis management.3 The HMS Plus™ System allows multiple tests to optimize your clinical decision. This results in lower procedural and operational costs.1, 2, 4
The portable ACT Plus™ Automated Coagulation Timer, our newest-generation automated coagulation platform, offers precise, reliable testing in heparin management and is well suited for all point-of-care testing, including: cardiovascular and vascular surgery, cardiac catheterization labs, critical care and hemodialysis units. The ACT Plus™ System has external data management (EDM) and connectivity-ready features. On-line technical support is also available.
Autotransfusion
The autoLog™ Autotransfusion System is a sophisticated device with a an exceptionally effective design that provides autologous blood during surgical procedures. Autologous red blood cell salvage is a safe, reliable and cost-effective method of returning red blood cells to a patient.
Platelet Therapy
More surgery teams are using the original technology of the Magellan™ Autologous Platelet Separator System to harness the natural healing power of platelets. Designed with input from experts in autologous blood component utilization, this lightweight, portable, closed-system separator requires only a small amount of a patient's blood and delivers consistent, platelet-rich plasma regardless of operator or patient variability. User flexibility allows the clinician to customize the platelet concentration in order to meet changing requirements.
1. Hill, AG, et al. More precise heparin and protamine management during cardiopulmonary bypass. Proceedings of the American Academy of Cardiovascular Perfusion. 1990;12-16.
2. Despotis, GJ, et al. More effective suppression of hemostasis system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost. 1996;67:2-8.
3. Despotis, GJ, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. J Thorac Cardiovascular Surg. 1995;110:46-54.
4. Bowie, JE, et al. Automated management of heparin anticoagulation in cardiovascular surgery. Proceedings of the American Academy of Cardiovascular Perfusion.
1985;6:1-5
|
